middle.news
Clarity Pharmaceuticals Launches Pivotal Phase III Trial for Prostate Cancer Imaging
2:07am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Clarity Pharmaceuticals Launches Pivotal Phase III Trial for Prostate Cancer Imaging
2:07am on Monday 2nd of June, 2025 AEST
Key Points
Phase III AMPLIFY trial commenced for Cu-SAR-bisPSMA in prostate cancer recurrence
Trial to enroll 220 participants across US and Australia
Cu-SAR-bisPSMA shows superior lesion detection and safety in earlier trials
Three FDA Fast Track Designations awarded to SAR-bisPSMA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CU6
OPEN ARTICLE